Premium
Use of Continuous Subcutaneous Growth Hormone‐Releasing Hormone (GHRH (1–29)NH 2 ) Infusions to Augment Growth Hormone Secretion and to Promote Growth
Author(s) -
BRAIN C.,
HINDMARSH P.C.,
PRINGLE P.J.,
BROOK C.G.D.
Publication year - 1989
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1989.tb17180.x
Subject(s) - medicine , endocrinology , growth hormone–releasing hormone , hormone , growth hormone , secretion , desensitization (medicine) , endocrine system , subcutaneous injection , receptor
. Brain, C., Hindmarsh, P.C., Pringle, P.J. and Brook, C.G.D. (Endocrine Unit, the Middlesex Hospital, London, UK). Use of continuous subcutaneous growth hormone‐releasing hormone (GHRH (1–29)NH 2 ) infusions to augment growth hormone secretion and to promote growth. Acta Paediatr Scand [Suppl] 349: 109, 1989. It has previously been shown that an 8‐day continuous subcutaneous infusion of GHRH (1–29)NH 2 in adult males augments growth hormone (GH) secretion with no evidence of desensitization of the response. The present report details the results of treatment with continuous subcutaneous infusions of CHRH (1–29)NH 2 in eight children aged 6–9 years with partial GH insufficiency. All the children showed augmentation of GH secretion and an increase in growth velocity after 3 and 6 months of therapy.